Document Page: First | Prev | Next | All | Image | This Release | Search
File: 120396_sep96_decls31_0001.txt
Subject: RECOMMENDATIONS OF THE AD HOC WORKING GROUP
Unit: OTSG
Parent Organization: HSC
Box ID: BX003203
Folder Title: RECOMMENDATIONS OF THE AD HOC GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE
Document Number: 1
Folder SEQ #: 175
%JLUIIL I UNCLASSIFIED
DEPARTMENT OF THE ARMY
OFFICE OF THE SURGEON GENERAL
S109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258
@y m
AMMTMN OF
SGPS-PSP 24 Aug 90
MEMORANDUM FOR LIEUTENANT GENERAL K F. LEDFORD
SUBJECT: Recommendations of the AD HOC Working Group for the
Medical Defense Against Biological Warfare
1. On 20 and 24 August 1990, the Ad Hoc Working Group for the
Medical Defense Against Biological Warfare formulated the
following recommendations.
a. Full scale production of the Anthrax vaccine (FDA
approved) should be initiated. Immediately utilizing existing
stocks of Anthrax vaccine, as manv troops as possible should
r a c a i v a I &XI] &Kw l@ As additional stocks become
available, personnel anould receive The CENTCON
Commander should determine which troops will receive the
vaccine first.
b. The production of the pentavalent toxoid (under IND)
for botulism should also be increased. The limited "on-hand"
stocks should be used for selected individuals and used under
its existing IND guidelines. in addition, anti-toxins and a
toxoid containing "F" should be made available as quickly as
possible.
c. Personnel and equipment should be placed in the theater
of operation and at the 10th Medical Lab, Germany, with the
capability of rapid diagnosis of BW agents and endemic disease
in clinically ill personnel. These teams would also train
on-site personnel. USAMRDC has agreed to perform this mission.
biotic chemoprophylaxis should
not be routinely used. If a BW threat is imminent,
doxycyclins, twice a day, should be given to selected
individuals. This therapy should be continued for at least 20
days and continued until at least all individuals receive two
doses of the Anthrax vaccine.
a. That CRDEC develop the capability for a rapid detection
system for BW attack.
2. USAMRDC personnel will speak with the manufacturer of the
Anthrax vaccine and the pentavalent toxoid on 27 August 1990
about expanding their production capabilities. In addition, on
28 August 1990, USAMRDC personnel will be speaking with FDA
representatives about using these products prior to the
completion of FDA testing requirements.
DECLASSIFIED UNCLASSIFIED
ON: 01 NOV 96
BY: SEC ARMY (DAMH) UNDER SEC 3.4 EO 12958
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 7 f:/Week-36/BX003203/RECOMMENDATIONS OF THE AD HOC GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE/recommendations of the ad hoc working group:11089615091832
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = RECOMMENDATIONS OF THE AD HOC GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE
Folder Seq # = 175
Subject = RECOMMENDATIONS OF THE AD HOC WORKING GROUP
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 08-NOV-1996